Additional Senior Leadership Team Members
Daniel Burch, M.D.
Daniel Burch, M.D., serves as global head of PPD® Biotech, which is devoted to finding Phase I-IV clinical development solutions for biotech and small to midsize pharma companies. Dr. Burch joined PPD in 2012, initially to lead the company’s neuroscience product development function. He was named PPD Biotech’s global medical officer in 2016 and global head in 2019.
Prior to PPD, Dr. Burch served as executive vice president and chief medical officer at CeNeRx BioPharma, a venture-backed, clinical-stage biotech, where he managed a portfolio of medicines focused on neuropsychiatric diseases. Prior to that, he headed the Neuroscience Medicines Development Centre at GlaxoSmithKline, where he had global responsibility for Phase II development through lifecycle management.
Earlier in his career at GSK and Abbvie, Dr. Burch held roles of increasing responsibility in a variety of global R&D and regional/global medical affairs functions across multiple therapeutic areas. Having successfully worked for more than 25 years in many strategic, operational and commercial aspects of drug development, Dr. Burch pursues a personal goal of promoting and facilitating more efficient and effective development of important medicines that have a strong, positive impact on patients and their families.
Dr. Burch earned his medical degree from the Vanderbilt University School of Medicine, where he completed a residency in internal medicine. Subsequently, he completed a fellowship and post-doctoral research in infectious diseases at the Washington University School of Medicine. He earned his MBA at the University of Pennsylvania’s Wharton School and has served for 15 years on the Forum on Neuroscience and Nervous System Disorders at the National Academy of Sciences.